View Older Stories View More Recent Stories
-
BridgeBio Pharma Inc. (BBIO) Misses Q3 EPS by 7c
-
BridgeBio Pharma (BBIO) PT Raised to $80 at H.C. Wainwright
-
BridgeBio Pharma (BBIO) PT Raised to $69 at Raymond James
-
BridgeBio Pharma (BBIO) PT Raised to $68 at Leerink Partners
-
BridgeBio Pharma (BBIO) PT Raised to $90 at Evercore ISI
-
Piper Sandler: 'Biotech Has a Heartbeat: 17 Stocks to Own Through YE25'
-
Truist Securities: 'Is Biotech Back?!'
-
Piper Sandler Sees 'A Good Setup for BridgeBio Pharma (BBIO) Shares to Outperform'
-
UBS Reiterates Buy Rating on BridgeBio Pharma (BBIO)
-
UBS Reiterates Buy Rating on BridgeBio Pharma (BBIO), Cites Confidence in Attruby
-
H.C. Wainwright Reiterates Buy Rating on BridgeBio Pharma (BBIO)
-
BridgeBio Pharma (BBIO) PT Raised to $82 at UBS on ADH1 Optimism
-
UBS Reiterates Buy Rating on BridgeBio Pharma (BBIO), Optimistic on Encaleret
-
TD Cowen on BridgeBio Pharma (BBIO): 'We anticipate an approval in 2026 with peak sales approaching $1B'
-
Truist Securities Reiterates Buy Rating on BridgeBio Pharma (BBIO)
-
Jefferies Reiterates Buy Rating on BridgeBio Pharma (BBIO)
-
H.C. Wainwright Reiterates Buy Rating on BridgeBio Pharma (BBIO)
-
BridgeBio Pharma (BBIO) Added to JPMorgan Positive Catalyst Watch List
-
BridgeBio Pharma (BBIO) PT Raised to $70 at JPMorgan
-
BridgeBio Pharma (BBIO) PT Raised to $70 at H.C. Wainwright
-
TD Cowen on BridgeBio Pharma (BBIO): 'Attruby Is a Winner'
-
BridgeBio Pharma (BBIO) PT Raised to $61 at Oppenheimer
-
BridgeBio Pharma Inc. (BBIO) Misses Q2 EPS by 20c
-
Raymond James Assumes BridgeBio Pharma (BBIO) at Outperform
-
Cantor Fitzgerald Reiterates Overweight Rating on BridgeBio Pharma (BBIO)
-
BridgeBio study finds ADH1 genetic condition underdiagnosed by 80%
-
Truist Securities Starts BridgeBio Pharma (BBIO) at Buy
-
H.C. Wainwright Reiterates Buy Rating on BridgeBio Pharma (BBIO)
-
Citi Reiterates Buy Rating on BridgeBio Pharma (BBIO)
-
Jefferies Starts BridgeBio Pharma (BBIO) at Buy
-
Helix Acquisition and BridgeBio Oncology receive SEC approval for merger
-
Oppenheimer Upgrades BridgeBio Pharma (BBIO) to Outperform
-
Cantor Fitzgerald Reiterates Overweight Rating on BridgeBio Pharma (BBIO)
-
Raymond James Reiterates Outperform Rating on BridgeBio Pharma (BBIO)
-
Citi Reiterates Buy Rating on BridgeBio Pharma (BBIO)
-
BridgeBio Pharma (BBIO) Raises $300 Million Through Partial Capped Monetization of BEYONTTRA European Royalty
-
Wolfe Research Starts BridgeBio Pharma (BBIO) at Outperform
-
H.C. Wainwright Reiterates Buy Rating on BridgeBio Pharma (BBIO)
-
Piper Sandler Highlights an 'Under-The-Radar 2H25 Catalyst' at BridgeBio Pharma (BBIO)
-
BridgeBio Pharma (BBIO) PT Raised to $42 at BMO Capital
-
Biotech stocks Q1 earnings review
-
BridgeBio Pharma Inc. (BBIO): Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study
-
BridgeBio Pharma Inc. (BBIO): First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study
-
BridgeBio Pharma Inc. (BBIO) call put ratio 1.2 calls to 1 put with a focus on May calls and puts as share price up 4.5%
-
BridgeBio Pharma (BBIO) PT Raised to $55 at Scotiabank
-
BridgeBio Pharma Inc. (BBIO) Tops Q1 EPS by 3c
-
Piper Sandler: 'What Biotech Names to Own in Market Volatility'
-
Piper Sandler on BridgeBio Pharma (BBIO): 'Attruby Launch In Early Innings Looks Strong'
-
Smid cap biotech investors must stop chasing binary events says Cantor Fitzgerald
-
Raymond James Reiterates Outperform Rating on BridgeBio Pharma (BBIO)

